Literature DB >> 30008110

Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis.

Nicolas Aide1,2, Thibault Salomon3, Charline Lasnon4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30008110     DOI： 10.1007/s00259-018-4087-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

1.  The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

Authors:  Jean-Mathieu Beauregard; Michael S Hofman; Grace Kong; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Reply to G. Keramida et al.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

3.  Report of the 6th International Workshop on PET in lymphoma.

Authors:  Cristina Nanni; Anne Ségolène Cottereau; Egesta Lopci; Caroline Bodet-Milin; Monica Coronado; Barbara Pro; Wong Seog Kim; Judith Trotman; Sally Barrington; Ulrich Duhrsen; Thierry Vander Borght; Elena Zamagni; Françoise Kraeber-Bodéré; Christina Messiou; Alain Rahmouni; Irène Buvat; Marc Andre; Mark Hertzberg; Wim Oyen; Olivier Casasnovas; Stefano Luminari; Laurent Garderet; Françoise Montravers; Carsten Kobe; Regine Kluge; Annibale Versari; Emanuele Zucca; Philippe Moreau; Bruce Cheson; Corinne Haioun; Andrea Gallamini; Michel Meignan
Journal:  Leuk Lymphoma       Date:  2017-03-07

4.  All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting.

Authors:  Sally F Barrington; Tom Sulkin; Adam Forbes; Peter W M Johnson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-02       Impact factor: 9.236

5.  Reply to: "All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting".

Authors:  Charline Lasnon; Blandine Enilorac; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-23       Impact factor: 9.236

6.  Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study.

Authors:  Laura L Boles Ponto; Yusuf Menda; Vincent A Magnotta; Torricia H Yamada; Natalie L Denburg; Susan K Schultz
Journal:  Int J Geriatr Psychiatry       Date:  2014-09-01       Impact factor: 3.485

7.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.

Authors:  P Lindholm; H Minn; S Leskinen-Kallio; J Bergman; U Ruotsalainen; H Joensuu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

8.  Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.

Authors:  Philipp Zimmer; Andreas Mierau; Wilhelm Bloch; Heiko K Strüder; Thorben Hülsdünker; Alexander Schenk; Leonie Fiebig; Freek T Baumann; Moritz Hahn; Nina Reinart; Michael Hallek; Thomas Elter
Journal:  Leuk Lymphoma       Date:  2014-06-05

Review 9.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

10.  Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score.

Authors:  Thibault Salomon; Catherine Nganoa; Anne-Claire Gac; Christophe Fruchart; Gandhi Damaj; Nicolas Aide; Charline Lasnon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-26       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.